Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Capecitabine
/ adverse effects
Colonic Neoplasms
/ drug therapy
Colorectal Neoplasms
/ drug therapy
Deoxycytidine
/ adverse effects
Disease-Free Survival
Drug Combinations
Female
Fluorouracil
/ adverse effects
Hospitals
Humans
Liver Neoplasms
/ secondary
Male
Middle Aged
Organoplatinum Compounds
/ adverse effects
Oxaliplatin
Rectal Neoplasms
/ drug therapy
Retrospective Studies
Colorectal cancer
capecitabine plus oxaliplatin
chemotherapy
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
08
2021
accepted:
07
03
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings. This study aimed to describe the therapeutic utility, efficacy and safety of a capecitabine plus oxaliplatin drug combination in patients with colorectal cancer. a review of medical records of sixty adult patients with histological diagnosis of colorectal cancer at Tygerberg Hospital between June 2012 and June 2017 was conducted. The overall response rate was assessed after a three cycle regime of capecitabine and oxaliplatin with the progression-free survival (PSF) results estimated using the Kaplan-Meier methods. among the 60 participants identified over the study period, the median age was 53 years with 45% being female (n=27). Records showed that 58.33% of patients had the colon as the primary site and 68.33% of patients had synchronous liver metastases at presentation. On average, all patients received 6 cycle regimes of capecitabine and oxaliplatin. Sixty percent of the patients received this treatment regime with palliative intent while in the radical-intent group, equal numbers of patients received the regime as either neoadjuvant or adjuvant. A liver resection was also performed in 20 patients (31.8%). The overall response rate was 69.6% with 13 patients attaining a complete response. Disease progression was reported in 30.4% and the 1-year progression free survival was 44.5% (95% CI: 0.31-0.57) while the 2-year progression free survival was 25.1% (95% CI: 0.14-0.38). Regarding safety, thrombocytopenia was the most frequent adverse event (18.5%) and overall, 15.1% of patients experienced grade 3 and 4 toxicity. a drug combination of capecitabine and oxaliplatin showed a good overall response rate and survival particularly in patients with resectable colorectal liver metastases.
Identifiants
pubmed: 36160274
doi: 10.11604/pamj.2022.42.141.31234
pii: PAMJ-42-141
pmc: PMC9463746
doi:
Substances chimiques
Drug Combinations
0
Organoplatinum Compounds
0
Oxaliplatin
04ZR38536J
Deoxycytidine
0W860991D6
Capecitabine
6804DJ8Z9U
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
141Informations de copyright
Copyright: Solomon Kibudde et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Lancet Oncol. 2013 Oct;14(11):1077-1085
pubmed: 24028813
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Eur J Cancer. 2015 Jan;51(2):166-76
pubmed: 25465185
Med Oncol. 2012 Jun;29(2):1020-9
pubmed: 21516482
J Surg Oncol. 2015 May;111(6):716-24
pubmed: 25864987
J Clin Oncol. 2008 Dec 20;26(36):5910-7
pubmed: 19018087
Br J Cancer. 2011 Jun 28;105(1):58-64
pubmed: 21673685
J Thorac Dis. 2017 Oct;9(Suppl 12):S1291-S1298
pubmed: 29119017
Anticancer Res. 2016 Apr;36(4):1949-54
pubmed: 27069185
Surgery. 2015 Jun;157(6):1065-72
pubmed: 25791030
Colorectal Dis. 2010 Jan;12(1):16-23
pubmed: 19220378
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S15-22
pubmed: 20011559
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
Chemother Res Pract. 2014;2014:520701
pubmed: 24818022
Br J Cancer. 2004 Mar 22;90(6):1190-7
pubmed: 15026800